PYC Therapeutics to Showcase PKD Drug Progress at World Nephrology Congress

The latest announcement is out from PYC Therapeutics Limited ( (AU:PYC) ).

PYC Therapeutics is advancing its PYC-003 drug candidate, designed to address the underlying cause of Polycystic Kidney Disease, as part of its portfolio of RNA-based precision medicines for genetic disorders. The company plans to showcase progress on PYC-003 in a poster presentation at the World Congress of Nephrology in Yokohama, underlining its strategic push into kidney disease indications.

The program is currently in a Phase 1a single ascending dose trial in both healthy volunteers and PKD patients, with comprehensive safety and efficacy data expected in the second half of 2026. PYC also aims to launch a Phase 1b multiple ascending dose study in PKD patients in the second quarter of 2026, with data anticipated in 2027, a clinical path that could strengthen its position in the renal genetic disease space if early results prove positive.

The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing a new generation of RNA therapies for patients with genetic diseases lacking treatment options. The ASX-listed group leverages a proprietary drug delivery platform to enhance the potency of precision medicines, targeting monogenic diseases that typically show higher probabilities of success in clinical development.

Average Trading Volume: 1,288,036

Technical Sentiment Signal: Buy

Current Market Cap: A$1.2B

For an in-depth examination of PYC stock, go to TipRanks’ Overview page.